N-acetylcysteine (NAC) is an antioxidant agent which has been shown to benefit patients with fulminant hepatic failure. We have examined its effect in patients with chronic liver disease undergoing orthotopic liver transplantation by giving NAC during operation. In a prospective, randomized, double-blind, placebo-controlled study of 50 patients, NAC appeared to induce mild vasodilatation, improve oxygen delivery and consumption, and reduce base deficit, but data interpretation was difficult. There were no significant effects on mortality, morbidity or postoperative graft function. (Br.
N-acetylcysteine (NAC) has an established role in the treatment of early paracetamol poisoning when it acts by replenishing intrahepatic glutathione stores. Glutathione is an antioxidant and prevents damage from the products of metabolism of paracetamol, but NAC is itself an antioxidant and has been shown to improve haemodynamic variables and outcome in established fulminant hepatic failure of various aetiologies [1] . Animal studies have shown that NAC may improve the survival of isolated perfused rat livers [2] and may improve liver function in pigs with liver ischaemia. NAC has been studied in other conditions where oxidant damage is the putative or known mechanism of injury, including adult respiratory distress syndrome (ARDS) [3] , idiopathic pulmonary fibrosis [4] , pancreatitis [5] and reperfusion injury after cardiac ischaemia [6] . We therefore gave NAC during liver transplantation in order to determine if the haemodynamic variables and outcome could be improved in the same way as in fulminant liver failure, and if graft reperfusion (which probably exerts some or all of its harmful effects by release of toxic oxidative free radicals) is modified.
Methods and results
Power analysis indicated that 50 patients would be required to show a 20 % increase in oxygen consumption at a significance level of P Ͻ 0.05, with 80 % power. In a prospective, randomized, doubleblind study, 50 adult patients with chronic end-stage liver disease undergoing orthotopic liver transplantation or re-transplantation received either NAC (n ϭ 25) or the same volume of 5 % glucose as a control (n ϭ 25). Approval was obtained from the Institutional Ethics Committee and informed consent from all patients.
A standardized anaesthetic regimen was used, including low-dose dopamine. Inotropic support and sodium bicarbonate were given according to our regimen. NAC (Parvolex) was given as a loading dose of 150 mg kg Ϫ1 over 15 min, followed by an infusion of 12.5 mg kg Ϫ1 h Ϫ1 for 4 h and then 6.25 mg kg Ϫ1 h Ϫ1 for the remainder of surgery. Haemodynamic measurements were obtained 1 h after induction of anaesthesia (I ϩ 1), after which the loading dose of test solution was given. Additional haemodynamic measurements were obtained 2 h after induction of anaesthesia (I ϩ 2), 30 min into the anhepatic stage (A ϩ 30), 5 min before reperfusion of the liver graft (R Ϫ 5) when the patient was receiving partial venovenous bypass with the portal vein clamped, 10 min after reperfusion (R ϩ 10), 1 h after reperfusion (R ϩ 60), at the end of the surgery (end) after which the test infusion was stopped, and 24 h after operation. Haemodynamic measurements included cardiac output from a pulmonary artery thermodilution catheter. Oxygen consumption was calculated using the Fick principle from standard formulae. Postoperative graft function and outcome variables were recorded.
There were no significant differences between patients who received NAC or placebo in age, preoperative condition assessed by Child-Pugh scoring, intraoperative use of blood products or measured blood loss. However, the 50 patients included five patients who were undergoing re-transplantation, all in the placebo group. Analysis showed that these patients differed markedly from first-time transplants; in particular they were much more acidotic, and this distorted the results. Re-transplant data were therefore excluded from further analysis. Both groups had a high initial cardiac index and calculated oxygen delivery, which further increased during surgery (table 1) . Oxygen delivery was significantly higher in the NAC group compared with controls at all intraoperative times. Cardiac index was higher (P Ͻ 0.05), with a lower mean arterial pressure (MAP) (P Ͻ 0.01 only at A ϩ 30) and a lower systemic vascular resistance index (SVRI) (P Ͻ 0.05) in the NAC group. Oxygen consumption was higher in the NAC group at all times but this was statistically significant only at I ϩ 2 (P Ͻ 0.05), immediately after dosing. After dosing until R ϩ 60, base deficit was lower in the NAC group (ns) despite receiving slightly less bicarbonate than controls (six patients received 350 mmol vs seven patients who received 695 mmol; ns).
It should be noted that the NAC group had a significantly higher cardiac index and lower SVRI (but no difference in MAP) before the test drug was given. The percentage increase in cardiac index in both groups after optimal volume loading and establishment of low-dose dopamine infusion was virtually the same (about 29 %).
Inotropic support was given as either boluses of adrenaline, infusions of either adrenaline or noradrenaline, higher doses of dopamine (Ͼ5 mg kg
) or boluses of ephedrine. There were no differences in requirements for catecholamine infusions, but NAC patients did receive more boluses of adrenaline (11/25 vs 2/20; P Ͻ 0.02) and ephedrine (10/25 vs 0/20; P ϭ 0.001, Fisher's exact test).
There were two intraoperative deaths, both in the control group (one from cardiac failure secondary to severe continuing blood loss, the other from intractable asystole on reperfusion). Up to 30 days after operation there were four deaths in the NAC group (one sepsis and multi-organ failure, one acute rejection, one sepsis and acute rejection, and one acute rejection and intracerebral bleed) and another in the control group (hyperacute rejection), with one more in the control group after 30 days (fatal haemorrhage from hepatic artery aneurysm) (ns). There was no difference in the rate of postoperative complications between groups, or in duration of ITU or hospital stay.
Median INR was higher in the NAC group compared with controls for the whole of the first week after operation, but the range was very wide and the differences were not statistically significant. Median serum AST concentration was also higher in the NAC group, and this was significant on day 6 (P Ͻ 0.05, Mann-Whitney U test). This may reflect the higher AST concentrations in those patients who suffered early episodes of rejection, although there was no significant difference in the total number of rejection episodes between the groups, or in eventual graft function.
Comment
Unfortunately, interpretation of haemodynamic data is made very difficult by pretreatment differences between groups. However, it is likely that NAC modifies haemodynamic variables when given during we found no significant improvement in base deficit and the only significant increase in oxygen consumption occurred before acidosis reached its greatest severity. The increase in oxygen delivery was less than that seen in fulminant hepatic failure [1] . We also noted that the improvement in oxygen consumption was only statistically significant immediately after the loading dose, possibly because plasma NAC concentrations were highest at this time, but our dosing regimen allowed plasma concentrations to decrease after this to a level too low to have an effect. We were not able to measure plasma concentrations of NAC, and in any case the optimal dose range for NAC is not known; we followed a regimen which has been used previously [1] .
